Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Sometimes an article pops up addressing a question we have been mulling over for quite some time. It so happened with a recent publication which shed new light on penem dosing for ICU patients[1]. Conducted at a single Belgian centre (sic!), a standard dose of meropenem (1 g IV q8h Continue reading Meropenem Dosing for VAP: High + Prolonged Beats Conventional Dosing
Solomkin et al. conclude that the efficacy and safety of eravacycline compares favorably to the control drug, ertapenem.[1] This top-level assessment is made with the usual caveats (insufficient statistical power, small sample size), but a few points deserve comment. Eravacycline is a fluorocycline; as a tetracycline derivative it follows into Continue reading Some Thoughts about Eravacycline Based on the Phase 2 cIAI Study
There are currently a total of 6 beta-lactam + beta-lactamase inhibitor combinations in clinical trials. It will be a steep learning curve for the pharma reps (and physicians) to understand the resistance classifications, the confusing ESBL definitions, the CRE nomenclature, and how this all matters in clinical practice, on the Continue reading What is the “Niche” for Ceftolozane / Tazobactam?